Clinical Trials Logo

Clinical Trial Summary

The acute respiratory distress syndrome (ARDS) remains a common and morbid complication of critical illness. Sepsis contribute to a lot of ARDS cases, but mechanisms by which non-pulmonary insults such as extrapulmonary sepsis propagate lung injury remain unclear. Most eukaryotic cells release small anuclear membrane-bound vesicles into the extracellular environment in either physiological or pathophysiological conditions, often called extracellular vesicles (EVs) .Through their cargo containing bioactive molecules such as proteins, mRNAs, and microRNAs and their interaction with target cells, EVs are recognized as important mediators of cellular communication. Mitochondrial contents are clearly present in EVs, and mitochondrial cargo within EVs have been shown to stimulate the production of proinflammatory cytokines, further enhancing LPS-induced inflammation. Among the mitochondrial contents, mtDNA was present at higher levels in EVs.Therefore, we hypothesis, EVs containing mtDNA play an important role in the occurrence and development of ARDS caused by extrapulmonary sepsis.


Clinical Trial Description

Inclusion criteria: Patients with ARDS caused by abdominal infection Exclusion criteria: age <18 years old or pregnancy; death or discharge within 24 hours after admission; advanced tumor The pathological information of the patients was collected on 24h, 48h after admission including demographic data, Acute Physiology and Chronic Health Evaluation (APACHE) II score , number of organ failures included in the Sequential Organ Failure Assessment (SOFA) score. The levels of lactate and inflammatory mediators (i.e., plasma C-reactive protein and procalcitonin) were detected on 24h and 48h after admission. All patients were followed up for 28 days, and all-cause mortality was recorded. The durations of mechanical ventilation and ICU stay were also recorded. The primary outcome was mortality on Day 28. Secondary outcomes included the ventilator days and ICU length of stay. Peripheral blood samples (2 mL) were collected on 24h and 48h after admission to the ICU. EVs were isolated from the plasma, and mtDNA concentration of plasma DNA was evaluated by RT-qPCR. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05061212
Study type Observational
Source Southeast University, China
Contact
Status Not yet recruiting
Phase
Start date October 1, 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04274296 - Advisory Lead ARDS Respirator Management
Active, not recruiting NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Terminated NCT04954014 - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Phase 2
Recruiting NCT03215316 - Screening Expiratory Flow Limitation by Flow-time Curve N/A
Recruiting NCT04115514 - Treatment of ARDS With Instilled T3 Phase 1/Phase 2
Not yet recruiting NCT05074758 - Characterization of the microVAScular Dysfunction in Covid-19 ARDS
Not yet recruiting NCT04556864 - Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
Recruiting NCT04174014 - Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography N/A
Not yet recruiting NCT04530188 - Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS Phase 3
Completed NCT03405038 - Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
Recruiting NCT04390360 - Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction N/A
Active, not recruiting NCT04382391 - Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms N/A
Completed NCT04008225 - Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System
Recruiting NCT04384731 - Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19 Phase 2
Recruiting NCT04692129 - Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients
Recruiting NCT04612608 - Assessing the Role of Inclined Positioning in Acute Respiratory Distress Syndrome Patients Recovery N/A
Recruiting NCT04445246 - Inhaled Iloprost for Suspected COVID-19 Respiratory Failure Phase 2
Recruiting NCT03525691 - Enhanced Lung Protective Ventilation With ECCO2R During ARDS N/A
Not yet recruiting NCT04397497 - Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) Phase 2
Recruiting NCT04503057 - Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS)